Format

Send to

Choose Destination
Virology. 2015 Oct;484:59-68. doi: 10.1016/j.virol.2015.04.027. Epub 2015 Jun 10.

Development of a human live attenuated West Nile infectious DNA vaccine: conceptual design of the vaccine candidate.

Author information

1
Southern Research, Division of Drug Discovery, Birmingham, Alabama, United States. Electronic address: vyamshchikov@southernresearch.org.

Abstract

West Nile virus has become an important epidemiological problem attracting significant attention of health authorities, mass media, and the public. Although there are promising advancements toward addressing the vaccine need, the perspectives of the commercial availability of the vaccine remain uncertain. To a large extent this is due to lack of a sustained interest for further commercial development of the vaccines already undergoing the preclinical and clinical development, and a predicted insignificant cost effectiveness of mass vaccination. There is a need for a safe, efficacious and cost effective vaccine, which can improve the feasibility of a targeted vaccination program. In the present report, we summarize the background, the rationale, and the choice of the development pathway that we selected for the design of a live attenuated human West Nile vaccine in a novel infectious DNA format.

KEYWORDS:

Human; Infectious DNA; Mice; Pathogenicity; Vaccine; Virulence; West Nile virus

PMID:
26071925
DOI:
10.1016/j.virol.2015.04.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center